SPRAVATO^® (esketamine)

SPRAVATO^® (esketamine) is an FDA-approved breakthrough treatment for treatment-resistant major depressive disorder (TRD) in adults. It is an intranasal medicine prescribed along with an oral antidepressant.

Clinical trials have shown a response rate of over 60% and a 52% remission rate in patients treated with SPRAVATO^® with minimal side effects.

Who Can Benefit from SPRAVATO^®?

SPRAVATO^® is FDA-approved to treat two specific types of depression in adults:

Treatment-Resistant Depression (TRD) Treatment-resistant depression is depression that does not improve with two or more antidepressants tried at adequate dosages and duration. Major Depressive Disorder with Suicidal Ideations If you have major depressive disorder (MDD) and have expressed suicidal thoughts or behaviors, SPRAVATO^® nasal spray may be an appropriate next step in treatment.

Insurance Coverage

Dallas Neurocare Therapy accepts the insurance providers listed below for SPRAVATO^® treatment.

Affordable Care Act (ACA)
Products Only

Our Treatment Amenities

At Dallas Neurocare, we prioritize your comfort and well-being during your SPRAVATO^® treatment sessions. Our goal is to create a soothing atmosphere to support your healing journey.

We offer private single-person treatment rooms equipped with large-screen TVs.
Relax and watch calming meditation music/videos or serene nature scenes to enhance your treatment experience.
Each room is thoughtfully designed to provide a tranquil environment, featuring dim lighting, a full recliner, and a cozy blanket.

SPRAVATO® (esketamine)

SPRAVATO® (esketamine) is an FDA-approved breakthrough treatment for treatment-resistant major depressive disorder (TRD) in adults. It is an intranasal medicine prescribed along with an oral antidepressant.

Who Can Benefit from SPRAVATO®?

SPRAVATO® is FDA-approved to treat two specific types of depression in adults: